Press Release The Noramco Group, an integrated North American-based API and drug product supply chain product and services provider, today announced a $25 million investment in its Halo Pharma ...

Envision Pharma Group said the deal would also enrich its global reach in medical affairs, while also providing 90TEN’s London-based team with significant geographical expansion opportunities.

Representing a groundbreaking initiative in pancreatic disease prevention and treatment, the strategic partnership can help CAP and Hengrui Pharma elevate China's healthcare capabilities in ...

Scientific communications organisation the Envision Pharma Group has revamped its top team, promoting David Thompson to chief executive officer as Brian Hepburn shifts to become its executive co ...

The Noramco Group is investing $25M into its Halo Pharma facility in Whippany, NJ to establish sterile injectable ...

Learn More About Halo Pharma’s New Sterile Manufacturing Capabilities at DCAT Week 2025— The Noramco Group, an integrated North American-based API and drug product supply chain product and ...

The Noramco Group’s investment will provide branded and generic pharmaceutical companies with a North American-based solution for sterile injectable manufacturing, strengthening the domestic ...